1 – 12 of 12
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders
(
- Contribution to journal › Article
-
Mark
α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
(
- Contribution to journal › Article
- 2022
-
Mark
Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors
(
- Contribution to journal › Article
-
Mark
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
(
- Contribution to journal › Article
-
Mark
Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD) : A Report of an International Research Collaboration Network
(
- Contribution to journal › Scientific review
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings
(
- Contribution to journal › Article
- 2020
-
Mark
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19
(
- Contribution to journal › Letter
- 2019
-
Mark
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
(
- Contribution to journal › Article
-
Mark
Determining clinically meaningful decline in preclinical Alzheimer disease
(
- Contribution to journal › Article
- 2005
-
Mark
The amyloid precursor protein(APP)of Alzheimer's disease and its paralog APLP2 modulate the Cu/Zn-NO-catalyzed degradation of glypican-1 heparan sulfate In vivo.
(
- Contribution to journal › Article